

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJHM1624

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JUL 02	LMEDLINE coverage updated
NEWS	3	JUL 02	SCISEARCH enhanced with complete author names
NEWS	4	JUL 02	CHEMCATS accession numbers revised
NEWS	5	JUL 02	CA/Capplus enhanced with utility model patents from China
NEWS	6	JUL 16	Capplus enhanced with French and German abstracts
NEWS	7	JUL 18	CA/Capplus patent coverage enhanced
NEWS	8	JUL 26	USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS	9	JUL 30	USGENE now available on STN
NEWS	10	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS	11	AUG 06	FSTA enhanced with new thesaurus edition
NEWS	12	AUG 13	CA/Capplus enhanced with additional kind codes for granted patents
NEWS	13	AUG 20	CA/Capplus enhanced with CAS indexing in pre-1907 records
NEWS	14	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS	15	AUG 27	USPATOLD now available on STN
NEWS	16	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS	17	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS	18	SEP 13	FORIS renamed to SOFIS
NEWS	19	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS	20	SEP 17	CA/Capplus enhanced with printed CA page images from 1967-1998
NEWS	21	SEP 17	Capplus coverage extended to include traditional medicine patents
NEWS	22	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	23	OCT 02	CA/Capplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS	24	OCT 19	BEILSTEIN updated with new compounds
NEWS EXPRESS	19	SEPTEMBER 2007:	CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 13:41:29 ON 22 OCT 2007

=> file registry

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 13:42:11 ON 22 OCT 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 19 OCT 2007 HIGHEST RN 951118-42-6

DICTIONARY FILE UPDATES: 19 OCT 2007 HIGHEST RN 951118-42-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007



Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10 series\10583335\10583335a.str



chain nodes :

10 17 18 19 26 27 28 29 31

ring nodes :

1 2 3 4 5 6 7 8 9 11 12 13 14 15 16 20 21 22 23 24 25

chain bonds :

2-11 4-10 7-28 9-27 13-17 16-26 17-18 17-19 17-20 23-29 26-31

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 11-12 11-16 12-13 13-14 14-15  
15-16 20-21 20-25 21-22 22-23 23-24 24-25

exact/norm bonds :

1-2 1-6 2-3 3-4 4-5 4-10 5-6 5-7 6-9 7-8 7-28 8-9 9-27 13-17 16-26  
17-18 17-19 17-20 20-21 20-25 21-22 22-23 23-24 23-29 24-25 26-31

exact bonds :

2-11

normalized bonds :

11-12 11-16 12-13 13-14 14-15 15-16

G1:H,Ak,Cb

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS  
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:CLASS 18:CLASS 19:CLASS  
20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:CLASS 27:CLASS 28:CLASS  
29:CLASS 31:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 13:43:09 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 89 TO ITERATE

100.0% PROCESSED 89 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 1214 TO 2346

PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 13:43:13 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 1639 TO ITERATE

100.0% PROCESSED 1639 ITERATIONS


25 ANSWERS

SEARCH TIME: 00.00.01

L3 25 SEA SSS FUL L1

=> d scan


L3 25 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
 IN Piperazine, 1-[[3-[(1-ethyl-4,7-dihydro-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxyphenyl]sulfonyl]-3,5-dimethyl-, (3R,5S)-rel- (9CI)  
 MF C25 H36 N6 O3 S2  
 Relative stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):3

L3 25 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
 IN Piperazine, 1-[[3-[(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxyphenyl]sulfonyl]-3,5-dimethyl-, (3R,5S)-rel- (9CI)  
 MF C24 H34 N6 O3 S2  
 Relative stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 25 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
 IN Piperazine, 1-[[3-[(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-3,5-dimethyl-, (3R,5S)-rel- (9CI)  
 MF C23 H32 N6 O3 S2  
 CI COM  
 Relative stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 25 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
 IN Piperazine, 1-[[3-[(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-(3-methylbutoxy)phenyl]sulfonyl]-4-ethyl- (9CI)  
 MF C26 H38 N6 O3 S2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> file caplus  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
173.00	173.21

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 13:43:52 ON 22 OCT 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 22 Oct 2007 VOL 147 ISS 18  
FILE LAST UPDATED: 21 Oct 2007 (20071021/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l3  
L4

4 L3

=> d l4 1-4 ibib abs hitstr

ACCESSION NUMBER: 2005:570896 CAPLUS  
DOCUMENT NUMBER: 143:97390

TITLE: Preparation of pyrazolopyrimidinethione derivatives for treatment of impotence  
INVENTOR(S): Li, Shuxin; Ren, Jianping; Zhao, Yanjin; Lv, Qiujuan; Guo, Jinhua

PATENT ASSIGNEE(S): The Institute of Radiation Medicine, Academy of Military Medical Sciences Pla, Peop. Rep. China  
PCT Int. Appl., 34 pp.


SOURCE: CODEN: PIXXD2  
Patent

DOCUMENT TYPE: Chinese  
LANGUAGE: Chinese

FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005058899	A1	20050630	WO 2004-CN1312	20041118
W:	AL, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CN 1629163	A	20050622	CN 2003-10118481	20031218
EP 1695976	A1	20060830	EP 2004-797343	20041118
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS			
IN 2006M00737	A	20070330	IN 2006-MN737	20060623
US 2007219220	A1	20070920	US 2007-583335	20070215
PRIORITY APPLN. INFO.:			CN 2003-10118481	A 20031218
			WO 2004-CN1312	W 20041118

OTHER SOURCE(S): CASREACT 143:97390; MARPAT 143:97390  
GI



AB Title compds. represented by the formula I [wherein R1-R3 = independently ((cyclo)alkoxy)alkyl, alkenyl or aryl; R4 = alkyl, alkenyl, (cyclo)alkoxy,

aryl; R5 = H, alkyl, alkenyl, (cyclo)alkoxy, aryl; R6 = H, (cyclo)alkyl, alkenyl, alkylcarbonyl; and pharmaceutically acceptable salts or solvates thereof] were prepared for treatment of impotence. For example, II was given in a multi-step synthesis starting from 4-amino-1-ethyl-3-propylpyrazole-5-carboxamide. I showed enhanced erectile response in

rats similar to that of Sildenafil. Thus, I and their pharmaceutical compns. are useful for the treatment of impotence and sexlessness, having high selectivity over PDE V, long action time, less side reactions, and no side effects of blood pressure decreasing and heart rate increasing.


IT 856190-47-1P  
RN: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of pyrazolopyrimidinethione derivs. for treatment of impotence)

RN 856190-47-1 CAPLUS

CN Piperazine,

1-[[3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-3,5-dimethyl-, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 856190-48-2P 856190-49-3P 856190-50-6P  
RN 856190-51-7P 856190-56-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of pyrazolopyrimidinethione derivs. for treatment of impotence)

RN 856190-48-2 CAPLUS

CN Piperazine,

1-[[3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-methoxyphenyl]sulfonyl]-3,5-dimethyl-, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 856190-49-3 CAPLUS

CN Piperazine,

1-[[3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxyphenyl]sulfonyl]-3,5-dimethyl-, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 856190-50-6 CAPLUS

CN Piperazine,

1-[[3-(1-ethyl-4,7-dihydro-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-methoxyphenyl]sulfonyl]-3,5-dimethyl-, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 856190-51-7 CAPLUS

CN Piperazine,

1-[[3-(1-ethyl-4,7-dihydro-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxyphenyl]sulfonyl]-3,5-dimethyl-, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 856190-56-2 CAPLUS

CN Piperazine,


1-[[3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-

L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
dipyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl]-3,5-dimethyl-, (3R,5S)-rel-,  
2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 856190-47-1  
CMF C23 H32 N6 O3 S2

Relative stereochemistry.



CM 2

CRN 77-92-9  
CMF C6 H8 O7



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:565628 CAPLUS  
DOCUMENT NUMBER: 143:211579

TITLE: Low-energy collision-induced dissociation of  
sildenafil thiono analogues: Gas-phase intramolecular  
nucleophilic substitution through ion-neutral  
complexes between a cationic substrate and a  
thione-containing neutral nucleophile

AUTHOR(S): Lee, Jaeick; Yoo, Hye Hyan; Kang, Min-Yung; Kim,  
Dong-Hyun  
CORPORATE SOURCE: Bioanalysis and Biotransformation Research Center,  
Korea Institute of Science and Technology, Seoul, S.  
Korea

SOURCE: Rapid Communications in Mass Spectrometry (2005),  
19(12), 1767-1770  
CODEN: RCMSEF; ISSN: 0951-4198

PUBLISHER: John Wiley & Sons Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Collisional-activation mass spectrometry of sildenafil [i.e.,  
1-[[3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-  
d]pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl]-4-(methyl)piperazine] and its thioxo analogs  
[e.g., 1-[[3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-  
d]pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl]-4-(methyl)piperazine] were  
reported.

IT 479073-72-8 479073-74-0 479073-79-5

479073-80-8 479073-86-4

RL: PRP (Properties)


(study of low energy collision-induced dissociation of sildenafil and

its thioxo analogs and study of gas-phase intramol. nucleophilic  
substitution through ion-neutral complexes between cationic substrate  
and thione-containing neutral nucleophile)

RN 479073-72-8 CAPLUS

CN Piperazine,

1-[[3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-  
d]pyrimidin-5-yl)-4-methoxyphenyl)sulfonyl]-4-methyl- (9CI) (CA INDEX  
NAME)




RN 479073-74-0 CAPLUS

CN Piperazine,

1-[[3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-  
d]pyrimidin-5-yl)-4-methoxyphenyl)sulfonyl]-4-ethyl- (9CI) (CA INDEX  
NAME)


L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 479073-79-5 CAPLUS

CN Piperazine,


1-[[3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-  
d]pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl]-4-methyl- (9CI) (CA INDEX  
NAME)



RN 479073-80-8 CAPLUS

CN Piperazine,

1-[[3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-  
d]pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl]-4-ethyl- (9CI) (CA INDEX  
NAME)




RN 479073-86-4 CAPLUS

CN Piperazine,

1-[[3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-  
d]pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR  
THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT



L4 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2007 ACS ON STN

ACCESSION NUMBER: 2004:524375 CAPLUS

DOCUMENT NUMBER: 141:420374

TITLE: Effects of a new selective phosphodiesterase type 5 inhibitor, KJH-1002, on the relaxation of rabbit corpus cavernosum tissue

AUTHOR(S): Cho, Eun Young; Chung, Sung-Hyun; Kim, Joong Hyup; Kim, Dong-Kyun; Jin, Changbae

CORPORATE SOURCE: Bioanalysis & Biotransformation Research Center, Korea

Institute of Science and Technology, Seoul, 130-650, S. Korea

JOURNAL OF APPLIED PHARMACOLOGY (2003), 11(4),

232-237

CODEN: JOAPA6; ISSN: 1225-6110

PUBLISHER: Korean Society of Applied Pharmacology

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The present study examined functional effects of a new selective phosphodiesterase type 5 inhibitor, 1-[4-ethoxy-3-(6,7-dihydro-1-methyl-7-thioxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)phenylsulfonfyl]-4-Me piperazine (KJH-1002), in the isolated rabbit corpus cavernosum (RCC). Relaxing effects of KJH-1002 were also compared with those of sildenafil, which is currently used as an oral therapy for penile erectile dysfunction. In the isolated RCC precontracted with phenylephrine, both KJH-1002 and sildenafil in the concentration range of 1 to 1000 nM, produced a comparable potentiation of the elec. field stimulation-induced relaxation in a concentration-dependent manner. In the sodium nitroprusside (SNP)-induced relaxation, the IC50 values, concns. of SNP required to produce a 50% relaxation of the phenylephrine-induced contraction, were significantly decreased to the similar extent by treatments with KJH-1002 and sildenafil. The results suggest that a new selective phosphodiesterase type 5 inhibitor, KJH-1002, has an augmentative effect on penile erection comparable to that of sildenafil and can be useful for the treatment of erectile dysfunction.

IT 479073-79-5  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(KJH-1002 phosphodiesterase type-5 inhibitor produced relaxing effect on rabbit corpus cavernosum and showed augmentative effect on penile erection comparable to that of sildenafil and may be useful in

erectile dysfunction treatment)

RN 479073-79-5 CAPLUS

CN Piperazine,

1-[[3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonfyl]-4-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS ON STN

ACCESSION NUMBER: 2002:597816 CAPLUS

DOCUMENT NUMBER: 138:55978

TITLE: Preparation of novel pyrazolopyrimidinethiones as phosphodiesterase V inhibitors for treating erectile dysfunction

INVENTOR(S): Kim, Joong-Hyup; Kim, Youseung; Choi, Kyung Il; Kim, Dong Hyun; Nam, Gilsu; Seo, Jae Hong

PATENT ASSIGNEE(S): Korea Institute of Science and Technology, S. Korea

SOURCE: PCT Int. Appl., 34 pp.

CODEN: PIIXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002102802	A1	20021227	WO 2002-KR1126	20020614
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG			
KR 2002095286	A	20021226	KR 2001-33382	20010614
AU 2002315822	A1	20030102	AU 2002-315822	20020614
EP 1395593	A1	20040310	EP 2002-741455	20020614
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2005505509	T	20050224	JP 2003-506275	20020614
US 2004176371	A1	20040909	US 2003-480191	20031209
PRIORITY APPL. INFO.:			KR 2001-33382	A 20010614
			WO 2002-KR1126	W 20020614


OTHER SOURCE(S): CASREACT 138:55978; MARPAT 138:55978

GI



1

L4 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)



REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS

FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)

AB The title compds. [I: R1, R2 = H, alkyl, cycloalkyl; R3 = alkyl, cycloalkyl or alkenyl which is unsubstituted or substituted; X = O, NR4; R4 = H, alkyl, cycloalkyl or alkenyl which is unsubstituted or substituted

with OH or alkoxy] which exhibit higher inhibitory activities against phosphodiesterase V as well as lower inhibitory activities against phosphodiesterase isoenzymes I, II and VI (biol. data given) and therefore are useful for the treatment of erectile dysfunction, were prepared E.g., a 3-step synthesis of I [R1 = Me; R2 = Pr; R3 = Et; X = NMe], starting from 5-(2-ethoxyphenyl)-1-methyl-3-propyl-1,6-dihydropyrazolo[4,3-d]pyrimidin-7-one, which showed IC50 of 0.59 nM against PDE V, was given.

IT 479073-72-8P 479073-74-OP 479073-76-2P

479073-79-5P 479073-80-8P 479073-82-OP

479073-86-4P 479073-87-5P 479073-88-6P

479073-90-OP 479073-92-2P 479073-93-3P

479073-94-4P 479073-96-6P 479073-97-7P

479073-98-8P 479074-00-5P 479074-01-6P


479074-02-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of novel pyrazolopyrimidinethiones as PDE5 inhibitors for treating erectile dysfunction)

RN 479073-72-8 CAPLUS

CN Piperazine,


1-[[3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-methoxyphenyl]sulfonfyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 479073-74-0 CAPLUS

CN Piperazine,


1-[[3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-methoxyphenyl]sulfonfyl]-4-ethyl- (9CI) (CA INDEX NAME)




L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 RN 479073-76-2 CAPLUS  
 CN 1-Piperazineethanol, 4-[[3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-methoxyphenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 479073-79-5 CAPLUS  
 CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 479073-80-8 CAPLUS  
 CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-ethyl- (9CI) (CA INDEX NAME)




RN 479073-82-0 CAPLUS  
 CN 1-Piperazineethanol, 4-[[3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 479073-90-0 CAPLUS  
 CN 1-Piperazineethanol, 4-[[3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxyphenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 479073-92-2 CAPLUS  
 CN Piperazine, 1-[[4-butoxy-3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)phenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 479073-93-3 CAPLUS  
 CN Piperazine, 1-[[4-butoxy-3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)phenyl]sulfonyl]-4-ethyl- (9CI) (CA INDEX NAME)


L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 479073-86-4 CAPLUS  
 CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 479073-87-5 CAPLUS  
 CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxyphenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 479073-88-6 CAPLUS  
 CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxyphenyl]sulfonyl]-4-ethyl- (9CI) (CA INDEX NAME)




L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 479073-94-4 CAPLUS  
 CN 1-Piperazineethanol, 4-[[4-butoxy-3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 479073-96-6 CAPLUS  
 CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-(2-methylpropoxy)phenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 479073-97-7 CAPLUS  
 CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-(2-methylpropoxy)phenyl]sulfonyl]-4-ethyl- (9CI) (CA INDEX NAME)




RN 479073-98-8 CAPLUS  
CN 1-Piperazineethanol, 4-[[3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo(4,3-d)pyrimidin-5-yl)-4-(2-methylpropoxy)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 479074-00-5 CAPLUS  
CN Piperazine,  
1-[[3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo(4,3-d)pyrimidin-5-yl)-4-(3-methylbutoxy)phenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 479074-01-6 CAPLUS  
CN Piperazine,  
1-[[3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo(4,3-d)pyrimidin-5-yl)-4-(3-methylbutoxy)phenyl]sulfonyl]-4-ethyl- (9CI) (CA INDEX NAME)



RN 479074-02-7 CAPLUS  
CN 1-Piperazineethanol, 4-[[3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo(4,3-d)pyrimidin-5-yl)-4-(3-methylbutoxy)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log hold

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

27.19

200.40

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-3.12

-3.12

SESSION WILL BE HELD FOR 120 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 13:51:56 ON 22 OCT 2007

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJHM1624

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page for STN Seminar Schedule - N. America  
NEWS 2 JUL 02 LMEDLINE coverage updated  
NEWS 3 JUL 02 SCISEARCH enhanced with complete author names  
NEWS 4 JUL 02 CHEMCATS accession numbers revised  
NEWS 5 JUL 02 CA/CAPplus enhanced with utility model patents from China  
NEWS 6 JUL 16 CAPplus enhanced with French and German abstracts  
NEWS 7 JUL 18 CA/CAPplus patent coverage enhanced  
NEWS 8 JUL 26 USPATFULL/USPAT2 enhanced with IPC reclassification  
NEWS 9 JUL 30 USGENE now available on STN  
NEWS 10 AUG 06 CAS REGISTRY enhanced with new experimental property tags  
NEWS 11 AUG 06 FSTA enhanced with new thesaurus edition  
NEWS 12 AUG 13 CA/CAPplus enhanced with additional kind codes for granted patents  
NEWS 13 AUG 20 CA/CAPplus enhanced with CAS indexing in pre-1907 records  
NEWS 14 AUG 27 Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB  
NEWS 15 AUG 27 USPATOLD now available on STN  
NEWS 16 AUG 28 CAS REGISTRY enhanced with additional experimental spectral property data  
NEWS 17 SEP 07 STN AnaVist, Version 2.0, now available with Derwent World Patents Index  
NEWS 18 SEP 13 FORIS renamed to SOFIS  
NEWS 19 SEP 13 INPADOCDB enhanced with monthly SDI frequency  
NEWS 20 SEP 17 CA/CAPplus enhanced with printed CA page images from 1967-1998  
NEWS 21 SEP 17 CAPplus coverage extended to include traditional medicine patents  
NEWS 22 SEP 24 EMBASE, EMBAL, and LEMBASE reloaded with enhancements  
NEWS 23 OCT 02 CA/CAPplus enhanced with pre-1907 records from Chemisches Zentralblatt  
NEWS 24 OCT 19 BEILSTEIN updated with new compounds

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2,